Table 4 Examples of inhibitors of STAT pathway components in clinical trials for cancer and immune-related disorders

CPL409116

JAKs/ROCK

Rheumatoid arthritis, psoriasis

1

R

NCT04670757

Abrocitinib (PF-04965842)

JAK1

Atopic dermatitis

3

C, C

NCT04345367, NCT03796676

Food allergy

1

N

NCT05069831

GSK2586184

JAK1

Psoriasis

2

C

NCT01782664

Systemic lupus erythematosus

1

R

NCT01953835

Itacitinib (INCB039110)

JAK1

Rheumatoid arthritis

2

C

NCT01626573

Plaque psoriasis

2

C

NCT01634087

Myeloproliferative neoplasms

2

C, C

NCT03144687, NCT01633372

Non-small cell lung cancer

2

A

NCT03425006

Graft versus host disease

2

R

NCT04200365

Hemophagocytosis lymphohistiocytosis

2

N

NCT05063110

B-cell lymphoma

1/2

C, A

NCT02018861, NCT02760485

Leukemia (acute myeloid, acute lymphocytic, myelodysplastic syndrome)

1

R

NCT03755414

T-cell leukemia

1

R

NCT03989466

Hepatocellular carcinoma

1

R

NCT04358185

Sarcoma

1

R

NCT03670069

SHR0302

JAK1

Rheumatoid arthritis

3

R

NCT04333771

Ankylosing spondylitis

2/3

R

NCT04481139

Atopic dermatitis

2/3

R

NCT04717310

Ulcerative colitis

2

C

NCT03675477

Crohn's disease

2

C

NCT03677648

Upadacitinib

JAK1

Inflammatory bowel disease (Crohn's disease)

3

A

NCT03345823

Atopic dermatitis

3

A

NCT04195698

Axial spondyloarthritis

3

A

NCT04169373

Baricitinib (INCB28050, LY3009104)

JAK1/2

Atopic dermatitis

3

C

NCT03435081

Juvenile idiopathic arthritis

3

A

NCT03773978

Sjogren's syndrome

1/2

C

NCT04916756

Graft versus host disease

1

R

NCT04131738

Momelotinib (CYT387)

JAK1/2

Myelofibrosis (primary, post-polycythemia vera, post-essential thrombocythemia)

3, 2

C, C

NCT02101268, NCT01969838

Jaktinib

JAK1/2

Myelofibrosis (primary, post-polycythemia vera, post-essential thrombocythemia)

2

R

NCT04217993

Acute graft versus host disease

2

N

NCT04971551

Atopic dermatitis

1/2

R

NCT04435392

Ruxolitinib (INCB018424)

JAK1/2

Alopecia areata

4

C

NCT03800979

Myelofibrosis

4

C

NCT01558739

Acute promyelocytic leukemia

4

R

NCT04446806

Polycythemia vera

3

C, C

NCT02038036, NCT02292446

Atopic dermatitis

3

C, R

NCT03745651, NCT04921969

Graft versus host disease

3

A

NCT03112603

Vitiligo

3

A

NCT04057573

TLL018

JAK1/TYK2

N/A

1

C

NCT04243083

Tofacitinib (CP-690550)

JAK1/JAK3

Alopecia areata

4

C

NCT03800979

Ulcerative colitis

4

A

NCT03281304

Rheumatoid arthritis

3

C

NCT00661661

Juvenile idiopathic arthritis

3

C

NCT02592434

Inflammatory eye disease

2

A

NCT03580343

VR588 (KN002)

JAKs

Severe asthma

1

C

NCT02740049

Brepocitinib (PF-06700841)

JAK1/TYK2

Psoriatic arthritis

2

C

NCT03963401

Systemic lupus erythematosus

2

R

NCT03845517

Cicatricial alopecia

2

R

NCT05076006

AZD1480

JAK2

Myelofibrosis (primary, post-polycythemia vera, essential thrombocythemia)

1

C

NCT00910728

Gandotinib (LY2784544)

JAK2

Myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera)

1, 2

C, A

NCT01520220, NCT01594723

Fedratinib (SAR302503)

JAK2

Myelofibrosis

2

C

NCT01523171, NCT01420770

Polycythemia vera, essential thrombocythemia

2

C

NCT03755518, NCT03952039

Ilginatinib (NS-018)

JAK2

Myelofibrosis (primary, post-polycythemia vera)

1/2, 2

C, N

NCT01423851, NCT04854096

Pacritinib (SB1518)

JAK2

Lymphoid malignancy (Hodgkin’s, mantle cell, indolent)

2

C

NCT01263899

Prostate cancer

2

R

NCT04635059

Myelofibrosis (essential thrombocythemia, polycythemia vera)

1,2

C

NCT00745550

Acute myeloid leukemia

1

C

NCT02323607

TQ05105

JAK2

Myelofibrosis

2

N

NCT05020652

Chronic graft versus host disease

1/2

R

NCT04944043

Hemophagocytic lymphohistiocytosis

1

R

NCT04326348

Myeloproliferative neoplasms

1

R

NCT04339400

Decernotinib (VX-509)

JAK3

Rheumatoid arthritis

2, 2/3

C, C

NCT01052194, NCT01830985

Ritlecitinib (PF-06651600)

JAK3

Alopecia areata

2

C

NCT02974868

Rheumatoid arthritis

2

C

NCT02969044

PF-06826647

TYK2

Psoriasis

2

C

NCT03895372

Danvatirsen (AZD9150)

STAT3

Carcinoma (non-small cell lung, pancreatic)

2

A

NCT01839604, NCT02983578, NCT03421353

Hepatocellular carcinoma

1

C

NCT01839604

Lymphoma (non-Hodgkin’s, DLBCL)

1

C

NCT03527147

TTI-101 (C188-9)

STAT3

Cancers (breast, head and neck, non-small cell lung, hepatocellular, colorectal, advanced cancer, squamous cell carcinoma, gastric adenocarcinoma and melanoma)

1

R

NCT03195699

CpG-STAT3 siRNA CAS3/SS3

STAT3

Lymphoma (B-cell—various)

1

R

NCT04995536

WP1066

STAT3

Glioblastoma, melanoma, neoplasm (brain)

1

A, R

NCT01904123, NCT04334863

Napabucasin (BBI608)

STAT3

Gastric and gastroesophageal cancer

3

C

NCT02178956

Colorectal carcinoma

3

C

NCT01830621

Pancreatic adenocarcinoma

3

C

NCT02993731

Glioblastoma

1/2

C

NCT02315534

OPB-51602

STAT3

Advanced cancer

1

C

NCT01423903

Hematological malignancy (multiple myeloma, non-Hodgkin’s lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia)

1

C

NCT01344876